Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies

Cristina Bergamaschi; Maria Pagoni; Margherita Rosati; Matthew Angel; Ifigeneia Tzannou; Margarita Vlachou; Ismini Darmani; Amirah Ullah; Jenifer Bear; Santhi Devasundaram; Robert Burns; Ioannis Baltadakis; Stavros Gigantes; Meletios A Dimopoulos; George N. Pavlakis; Evangelos Terpos; Barbara K. Felber

doi:10.2139/ssrn.4030553

Related publications

Article2022

Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies

Cristina Bergamaschi, Maria Pagoni, Margherita Rosati, Matthew Angel, Ifigeneia Tzannou, Margarita Vlachou, Ismini Darmani, Amirah Ullah, Jenifer Bear, Santhi Devasundaram, Robert Burns, Ioannis Baltadakis, Stavros Gigantes, Meletios A Dimopoulos, George N. Pavlakis, Evangelos Terpos, Barbara K. Felber

Article2023

Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations

Margherita Rosati, Evangelos Terpos, Philip Homan, Cristina Bergamaschi, Sevasti Karaliota, Ioannis Ntanasis‐Stathopoulos, Santhi Devasundaram, Jenifer Bear, Robert Burns, Tina Bagratuni, Ioannis P. Trougakos, Meletios A Dimopoulos, George N. Pavlakis, Barbara K. Felber

Article2022

SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies

Evangelos Terpos, Despina Fotiou, Vangelis Karalis, Ioannis Ntanasis‐Stathopoulos, Aimilia D. Sklirou, Maria Gavriatopoulou, Panagiotis Malandrakis, Vassiliki A. Iconomidou, Efstathios Kastritis, Ioannis P. Trougakos, Meletios A Dimopoulos

Article2021

Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine

Maria Gavriatopoulou, Evangelos Terpos, Panagiotis Malandrakis, Ioannis Ntanasis‐Stathopoulos, Αlexandros Briasoulis, Sentiljana Gumeni, Despina Fotiou, Eleni‐Dimitra Papanagnou, Magdalini Migkou, Foteini Theodorakakou, Evangelos Eleutherakis‐Papaiakovou, Nikolaos Kanellias, Ioannis P. Trougakos, Efstathios Kastritis, Meletios A Dimopoulos

Article2021

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients

Ioannis P. Trougakos, Evangelos Terpos, Christina Zirou, Aimilia D. Sklirou, Filia Apostolakou, Sentiljana Gumeni, Ioanna Charitaki, Eleni‐Dimitra Papanagnou, Tina Bagratuni, Christine‐Ivy Liacos, Andreas Scorilas, Eleni Korompoki, Ioannis Papassotiriou, Efstathios Kastritis, Meletios A Dimopoulos

Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies

Discussion(0)

Related publications

Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies

Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations

SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies

Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients